Business Wire

LevelBlue and Akamai Partner to Launch New Managed Web Application and API Protection Services

12.8.2025 14:00:00 CEST | Business Wire | Press Release

Share

LevelBlue, a leading provider of managed security services, strategic consulting, and threat intelligence, today announced the launch of its Managed Web Application and API Protection (WAAP) security service, designed to deliver adaptive, always-on protection that can reduce risk and operational overhead for web application and API security. Powered by Akamai’s industry-leading App & API Protector technology, LevelBlue Managed WAAP combines next-gen web application firewall (WAF), distributed-denial-of service (DDoS) mitigation, bot protection, and foundational API security capabilities paired with LevelBlue’s dedicated WAAP Operations team.

Organizations globally are rapidly scaling their use of applications and APIs to power digital-first strategies. According to Enterprise Strategy Group, the average number of web applications per organization is expected to grow from 145 to more than 200 within two years. Simultaneously, the number of organizations with more than half of their applications using APIs will rise from 32% to 80%. Among the most critical challenges security teams face are:

  • Discovering application and API deployments
  • Scaling adequate protections
  • Swiftly identifying and mitigating attacks
  • Ensuring security does not impact performance

In addition, many struggle with staff constraints and an expertise gap. As environments grow more complex, half of midmarket organizations say it's harder to secure web apps and APIs than it was just two years ago, and so many are seeking external help and simplified, consolidated solutions. LevelBlue Managed WAAP directly addresses these needs, delivering measurable security outcomes while streamlining operations.

“Today, a surprising number of organizations rely on multiple tools that are not purpose-built for web application and API security—leading to complexity, silos, and rising costs,” said Sundhar Annamalai, president of LevelBlue. “LevelBlue offers an alternative: proven services that consolidate and simplify protections with predictable investment. By combining LevelBlue’s operational expertise with Akamai’s proven technology, organizations can stay ahead of evolving threats and create cyber resilience for critical digital capabilities.”

LevelBlue Managed WAAP is available in two tiers, Essential and Advanced, giving organizations the flexibility to choose a service level that best meets their needs. Core benefits include:

  • Access 24/7 WAAP expertise: Gain a fully operational team of specialists delivering around-the-clock support, monitoring, and advisory to improve WAAP protection.
  • Discover and secure critical assets: Automatically identify and classify web apps and APIs—prioritize those exposed or handling sensitive data, and scale protection as needed.
  • AI-Powered Threat Defense: Combine AI-driven detection with global threat intelligence to spot anomalies, adapt to new attack vectors, and stay ahead of threats.
  • Streamlined Security Management: Eliminate manual tuning with expert-led, automated policy management, boosting efficiency, reducing false positives, and aligning with modern DevOps workflows.

“In 2024 alone, Akamai saw over 311 billion web app attacks. As AI accelerates, threats are harder to spot, and security is tougher to control,” said Rupesh Chokshi, Senior Vice President and General Manager of Akamai’s Application Security Portfolio. “Akamai and LevelBlue’s partnership gives customers access to a trusted, reliable team that combines industry-leading technology with the deep operational expertise of one of the world’s largest MSSPs. It’s a powerful combination with a flexible solution that can fast-track organizations to resilient protection and compliance."

To learn more about LevelBlue Managed WAAP services, please visit here.

About LevelBlue
We simplify cybersecurity through award-winning managed services, experienced strategic consulting, threat intelligence, and renowned research. Our team is a seamless extension of yours, providing transparency and visibility into security posture and continuously working to strengthen it.

We harness security data from numerous sources and enrich it with artificial intelligence to deliver real-time threat intelligence- this enables more accurate and precise decision making. With a large, always-on global presence, LevelBlue sets the standard for cybersecurity today and tomorrow. We easily and effectively manage risk, so you can focus on your business.

Welcome to LevelBlue. Cybersecurity. Simplified. Learn more at www.levelblue.com.

About Akamai
Akamai is the cybersecurity and cloud computing company that powers and protects business online. Our market-leading security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. Akamai’s full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. Global enterprises trust Akamai to provide the industry-leading reliability, scale, and expertise they need to grow their business with confidence. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250812788980/en/

Contacts

Media Contact
Jessica Bettencourt
Inkhouse for LevelBlue
levelblue@inkhouse.com
(774) 451-5142

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye